{"id":"NCT03801707","sponsor":"Ohio State University","briefTitle":"Utilization of Hepatitis C Positive Kidneys in Negative Recipients","officialTitle":"An Open Label, Proof of Concept Study to Evaluate the Feasibility and Safety of Kidney Transplant From HCV Positive Donors Into HCV Negative Recipient","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-03-22","primaryCompletion":"2021-04-28","completion":"2021-04-30","firstPosted":"2019-01-11","resultsPosted":"2023-09-13","lastUpdate":"2023-09-13"},"enrollment":54,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Kidney Transplant","Hepatitis C","HCV"],"interventions":[{"type":"DRUG","name":"Sofosbuvir / Velpatasvir Oral Tablet [Epclusa]","otherNames":["Epclusa"]},{"type":"DRUG","name":"Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET]","otherNames":["Mavyret"]}],"arms":[{"label":"Intervention group","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and feasibility of transplanting kidneys from Hepatitis C virus (HCV) infected donors into recipients without HCV infection","primaryOutcome":{"measure":"Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment","timeFrame":"12 weeks","effectByArm":[{"arm":"Intervention Group","deltaMin":28,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["29292608","26569658","26571066","26476290","26575258","27444413","29886154","29672891","29507971"],"seeAlso":["https://www.usrds.org/annual-data-report/current-adr/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":30},"commonTop":["Liver enzyme elevation"]}}